secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001493152-26-016308
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical secures exclusive U.S. distribution rights for HEMOBLAST Bellows hemostat
--------------------------------------------------------------------------------

- Paid Dilon a $5.0M exclusivity fee; no minimum purchase requirements.
- Hired approximately 20 Dilon U.S. sales personnel to commercialize the product.
- HEMOBLAST Bellows is an FDA-approved collagen/thrombin/chondroitin sulfate hemostatic powder.
- Addresses estimated $2.0 billion global addressable market for hemostatic products.
- Xtant to update FY2026 guidance upon Q1 2026 earnings release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226016308/0001493152-26-016308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226016308/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer